Home » CV Therapeutics Launches 1000 mg Ranexa Tablet
CV Therapeutics Launches 1000 mg Ranexa Tablet
CV Therapeutics, Inc. announced the U.S. Food and Drug Administration approval and U.S. product launch of the 1000 mg tablet of Ranexa (ranolazine extended-release tablets).
CV Therapeutics
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May